| Title |
A phase II dose-ranging study of mirabegron in patients with overactive bladder
|
|---|---|
| Published in |
International Urogynecology Journal & Pelvic Floor Dysfunction, March 2013
|
| DOI | 10.1007/s00192-013-2042-x |
| Pubmed ID | |
| Authors |
Christopher R. Chapple, Vladimir Dvorak, Pjotr Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte Bosman, Peter Boerrigter, Ted Drogendijk, Arwin Ridder, Ingrid Van Der Putten-Slob, Osamu Yamaguchi, On behalf of the Dragon Investigator Group |
| Abstract |
Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Egypt | 1 | 1% |
| Unknown | 70 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 18% |
| Researcher | 9 | 12% |
| Student > Postgraduate | 8 | 11% |
| Student > Master | 7 | 10% |
| Other | 4 | 5% |
| Other | 15 | 21% |
| Unknown | 17 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 34% |
| Nursing and Health Professions | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 11 | 15% |
| Unknown | 22 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2020.
All research outputs
#3,415,350
of 25,374,647 outputs
Outputs from International Urogynecology Journal & Pelvic Floor Dysfunction
#219
of 2,900 outputs
Outputs of similar age
#27,746
of 208,503 outputs
Outputs of similar age from International Urogynecology Journal & Pelvic Floor Dysfunction
#5
of 26 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,900 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,503 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.